Oppenheimer Asset Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,576
| Closed | -$960K | – | 1272 |
|
|
2021
Q3 | $960K | Sell |
5,576
-324
| -5% | -$42.4K | 0.01% | 758 |
|
|
2021
Q2 | $740K | Sell |
5,900
-188
| -3% | -$23.7K | 0.01% | 836 |
|
|
2021
Q1 | $826K | Sell |
6,088
-149
| -2% | -$19.2K | 0.01% | 775 |
|
|
2020
Q4 | $798K | Sell |
6,237
-466
| -7% | -$54.6K | 0.01% | 754 |
|
|
2020
Q3 | $754K | Buy |
+6,703
| New | +$667K | 0.01% | 696 |
|
|
2020
Q2 | – | Sell |
-1,468
| Closed | -$132K | – | 1505 |
|
|
2020
Q1 | $132K | Sell |
1,468
-64
| -4% | -$4.97K | ﹤0.01% | 1051 |
|
|
2019
Q4 | $81K | Sell |
1,532
-3
| -0.2% | -$137 | ﹤0.01% | 1246 |
|
|
2019
Q3 | $61K | Sell |
1,535
-94
| -6% | -$4.08K | ﹤0.01% | 1309 |
|
|
2019
Q2 | $67K | Sell |
1,629
-267
| -14% | -$11.1K | ﹤0.01% | 1320 |
|
|
2019
Q1 | $88K | Sell |
1,896
-698
| -27% | -$30.6K | ﹤0.01% | 1251 |
|
|
2018
Q4 | $113K | Buy |
+2,594
| New | +$130K | ﹤0.01% | 1163 |
|
|
2017
Q3 | – | Sell |
-837
| Closed | -$25K | – | 1724 |
|
|
2017
Q2 | $25K | Sell |
837
-12
| -1% | -$348 | ﹤0.01% | 1458 |
|
|
2017
Q1 | $22K | Buy |
+849
| New | +$22.4K | ﹤0.01% | 1467 |
|
Oppenheimer Asset Management's XLRN Position: Q4 2021 in Review
Oppenheimer Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 5,576 shares — an estimated $960K sold.
Oppenheimer Asset Management first reported a position in XLRN in Q1 2017 and held it in 13 quarters. The position peaked at $960K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Oppenheimer Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Oppenheimer Asset Management sold 5,576 Acceleron Pharma shares in Q4 2021, an estimated $960K.
- Oppenheimer Asset Management first reported a position in Acceleron Pharma in Q1 2017 and held it in 13 quarters.
- Oppenheimer Asset Management's Acceleron Pharma position peaked at $960K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Oppenheimer Asset Management's 13F filing for Q4 2021, filed 2 Feb 2022.